AVXL made money on paper and burned more cash in the three months ended June 30. That is the filing in one sentence, and it is an unusually important one for a clinical-stage drug developer.
Operating income swung from a $6.5 million loss in the three months ended March 31 to $6.7 million of income. Net income moved from negative $5.3 million to positive $7.8 million, or 8 cents a diluted share.
The cash statement went the other way. Operating cash flow deteriorated from negative $11.6 million to negative $20.7 million, while cash fell from $127.4 million to $118.3 million. The company did not disclose a single cause for that cash-flow change in the supplied filing receipts.
The accounting lines add noise to the profit swing. Stock compensation moved from $314,000 to negative $17.1 million, a non-cash change, and the reported diluted-share figure jumps from 92.7 million to 92.9 billion. Those figures make the income statement harder to read as a clean measure of the business’s cash-generating progress.
Management also disclosed a control problem, not merely a research expense problem. AVXL said its disclosure controls were ineffective at June 30 because of a material weakness previously described in its amended annual report.
"Based on this evaluation, our Principal Executive Officer and our Principal Financial Officer concluded that our disclosure controls and procedures were not effective as of June 30, 2026 due to the material weakness in internal control over financial reporting as described in our Form 10-K/A for the fiscal year ended September 30, 2025, filed with the SEC on August 28, 2026 (the “2025 Form 10-K/A”)."
AVXL, 10-Q filed August 28, 2026.
That disclosure does not erase the reported profit. It does put a footnote under how confidently readers can compare this period with the prior one, especially alongside the unusual stock-compensation and share-count figures.
The business is still spending on the pipeline. Clinical pharmacology studies increased by $1.1 million, mainly for a drug-drug interaction study that began in the third quarter of fiscal 2026 and manufacturing for an ADME study expected to start in the fourth quarter. That is a concrete use of resources, even as the income statement shows a positive operating result.
The company’s liquidity language is correspondingly cautious:
"Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount and timing of our working capital requirements."
AVXL, 10-Q filed August 28, 2026.
In plain English, AVXL has cash, but the company says the timing and size of its funding needs cannot be pinned down precisely. That matters more when operating cash flow is negative and the latest period’s profit contains the negative $17.1 million non-cash stock-compensation figure.
There is also a governance bill attached to the period. Legal and professional expenses rose by approximately $2.2 million because of the Special Committee review that resulted in the termination of the former CEO and related matters. The company separately disclosed shareholder litigation, so the reporting burden is not confined to the accounting controls issue.
AVXL’s latest close was $2.71 on May 21, down 1.5% that day. The next quarterly report’s comparison of operating cash flow, cash, and the status of the material weakness will clarify whether this was a single-period accounting oddity or part of a continuing reporting issue and funding uncertainty.
AVXL reported positive operating income and net income for the three months ended June 30, while operating cash flow remained negative and disclosure controls were ineffective.